Navigation Links
FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder
Date:8/2/2010

normal plasma. No albumin is added as a stabilizer. wilate® is exclusively derived from large pools of human plasma collected in U.S. FDA approved plasma donation centers.  wilate® contains a VWF triplet structure and VWF mulitmeric distribution similar to normal human plasma.

According to the National Institutes of Health, VWD is the most common inherited bleeding disorder and occurs in about 1 out of every 100 to 1,000 people. "The FDA orphan drug exclusivity approval for wilate® confirms Octapharma's decision to focus exclusively on the treatment of von Willebrand patients and further demonstrates Octapharma's commitment to the continued advancement of human protein therapies," said Nielsen.

For more information on wilate®, please visit www.wilateusa.com.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product,

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
5. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
6. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
7. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
8. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
9. Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
10. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
11. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Balloon Market Investment Report, 2014-2016" report to their ... medical device in percutaneous coronary intervention (PCI), serves not ... as a device for pre-/post-stent dilatations. Therefore, the development ... of PCI. As national economy develops and ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... 2014  KIYATEC announced today that it has ... Research (SBIR) Phase II Contract from the National ... and centers that comprise the National Institutes of ... year award, KIYATEC will expand its 3D breast ... forefront of cancer therapy strategies: 1) cancer,s interaction ...
Breaking Medicine Technology:China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3
... (NASDAQ: OPTR ) today announced the presentation ... (DDW) conference highlighting additional analyses of data from Phase ... the treatment of Clostridium difficile infection (CDI). ... first analysis aimed to identify risk factors associated with ...
... MINNEAPOLIS, May 9, 2011 BioDrain Medical, Inc. (OTC ... FDA-cleared Streamway™ System for automated surgical fluid disposal, announced ... ("EKN"), a New York-based registered broker/dealer, as its exclusive ... terms of the agreement, EKN will assist the Company ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent 2BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent 3
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... The American College of Chest Physicians (CHEST) together ... at the annual congress of CTS that CHEST ... Clinicians specializing in pulmonary, critical care, and sleep ... participate in the event, slated for spring 2016. ... rich educational experiences including hands-on simulation training, keynote ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 ... the Neighborhood Mission (Misión Barrio Adentro), which ... the healthcare system (see Section 6.1.3.). In ... in an Autonomous Service of Pharmaceutical Elaborations ... plant, which provides medicines at a cheaper ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... Salt Lake City, UT (PRWEB) September 18, 2014 ... across North America will be recognizing their shared fundraising ... on Thursday, Sept. 25. , The first-ever Dance ... of more than $20 million projected to be raised ... at their community’s CMN Hospital. Donations generated through Dance ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... services company standardizes on AVG Network Edition , ... ... Pyramid Healthcare, founded in 1999, provides behavioral healthcare services for ... and behavioral problems. The company has 23 locations across Pennsylvania, ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that they ... with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) ... the initial $7.5 million payment in connection with the ... up to an additional $15 million in product sales ...
... Immucor, Inc.,(Nasdaq: BLUD ), a global leader ... reported financial results,for the fiscal second quarter ended November 30, ... -- Revenue for the fiscal second quarter ... the same period last year. , ...
... of America,Inc. announced the formation of ROSA of ... ROSA of South Alabama is a joint ... P.C., Monroeville Radiation -,Oncology, P.C., and South Alabama ... of America, Inc. ROSA of South,Alabama will ...
... The following is a statement by Lois Aronstein, ... State address put forth recommendations on a number of ... financial security of New Yorkers of all ages.AARP commends ... Plus Program to 200 percent of the federal poverty ...
... also bolsters tie between vitamin D and the brain ... have identified nine genes that might make people more ... confirmed earlier reports that a variation in the vitamin ... risk for Alzheimer,s. Low levels of vitamin D ...
Cached Medicine News:Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 2Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 3Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 4Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 2Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 3Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 5Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 6Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 7Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 8Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 9Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2Health News:9 Genes Are Linked to Alzheimer's 2
... Ad-Techs Foramen Ovale Electrodes provide you ... These electrodes offer the same proven design ... that they are placed using an introducing ... a smaller electrode body diameter, 3 to ...
... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...
... is designed to replace the carpal scaphoid bone. ... pole which fits under a shelf formed in ... suture hole on the proximal hole for suture ... the early postoperative period until a firm capsuloligamentous ...
... two-piece Titanium (Ti-6Al-4V) screw offered in two ... of lengths. The two pieces are loaded ... A single instrument set contains all items ... Standard and Mini Kompressor Compression Screws. , ...
Medicine Products: